Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Reports have focused on the emergence of moulds as pathogens in recipients of hematopoietic stem cell transplants. To review the incidence of and risks for mould infections, we examined the records of 5589 patients who underwent hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Research Center (Seattle) from 1985 through 1999. After 1992, the incidence of invasive aspergillosis increased in allograft recipients and remained high through the 1990s. Infections with non-fumigatus Aspergillus species, Fusarium species, and Zygomycetes increased during the late 1990s, especially in patients who received multiple transplants. Although infection caused by Scedosporium species was common in patients who had neutropenia, infection caused by Zygomycetes typically occurred later after transplantation, when patients had graft-versus-host disease. The overall 1-year survival rate was equally poor (similar20%) for all patients with mould infections. The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B--resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.

[1]  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000 .

[2]  I. Marino,et al.  Infections due to dematiaceous fungi in organ transplant recipients: case report and review. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Lloyd D. Fisher,et al.  2. Biostatistics: A Methodology for the Health Sciences , 1994 .

[4]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[5]  S. Heimfeld,et al.  Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. , 1999, Blood.

[6]  M. Boeckh,et al.  Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Kontoyiannis,et al.  Zygomycosis in the 1990s in a tertiary-care cancer center. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  G. Alangaden,et al.  Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. , 1994, Bone marrow transplantation.

[9]  E. Anaissie,et al.  Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. , 1997, Blood.

[10]  J. Latgé,et al.  Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Ribes,et al.  Zygomycetes in human disease. , 2000, Clinical microbiology reviews.

[12]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[13]  R. Storb,et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  R Sylvester,et al.  An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. , 1998, The Journal of infection.

[16]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[17]  D. Denning,et al.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. , 1997, The Journal of antimicrobial chemotherapy.

[18]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[19]  V. Yu,et al.  Cirrhotic fever in the 1990s: a prospective study with clinical implications. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  V. Morrison,et al.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. , 1994, The American journal of medicine.

[21]  A. Nagler,et al.  Invasive fungal sinusitis in patients undergoing bone marrow transplantation. , 1993, Bone marrow transplantation.

[22]  J. Perfect,et al.  The new fungal opportunists are coming. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Storb,et al.  Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. , 1991, Bone marrow transplantation.

[24]  P. Cernoch,et al.  Dematiaceous fungi are an increasing cause of human disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Y. Ohnishi,et al.  Alteration of Cell Wall Composition Leads to Amphotericin B Resistance in Aspergillus flavus , 1999, Microbiology and immunology.

[26]  W. Leisenring,et al.  The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients , 1998, Medicine.

[27]  Yvonne M Clayton,et al.  Book Review: Medically Important Fungi: A Guide to Identification , 1977 .

[28]  S. Sanche,et al.  In Vitro Amphotericin B Resistance in Clinical Isolates of Aspergillus terreus, with a Head-to-Head Comparison to Voriconazole , 1999, Journal of Clinical Microbiology.

[29]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.